Idera Pharmaceuticals (NASDAQ: IDRA)
Some price data may be temporarily unavailable.
Idera Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Idera Pharmaceuticals Company Info
Aceragen, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the research and development of medications for rare and orphan diseases. The firm’s product portfolio includes ACG-801 and ACG-701, which targets Farber Disease, Melioidosis, and Cystic Fibrosis. The company was founded in 1989 and is headquartered in Exton, PA.
News & Analysis
Why Idera Pharmaceuticals Stock Is Crashing Today
The company's experimental cancer drug flopped in a late-stage study.
3 Beaten-Down Biotech Stocks: Can They Recover?
Is there a light at the end of the tunnel?
Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today
Investors are cheering the orphan drug specialist's decision to raise a nice chunk of capital via a public offering.
Why American Airlines, Idera Pharmaceuticals, and RH Holdings Slumped Today
From a scuttled merger to tariff troubles, see why these three companies fell hard today.
Why Idera Pharmaceuticals Is Sinking Today
Shares plunge after its proposed merger is called off. Here's what investors need to know.
Here's Why Idera Pharmaceuticals Fell as Much as 15.4% Today
The company released preliminary data from an important phase 1/2 study.
Why II-VI, Sanmina, and Idera Pharmaceuticals Slumped Today
Find out which company announced a merger.
BioCryst Pharmaceuticals' and Idera Pharmaceuticals' Merger Announcement Gets No Love
Is this a merger out of weakness and necessity? Wall Street might think so.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.